Detalhe da pesquisa
1.
Phase 1b study of pan-AKT inhibitor vevorisertib alone or with paclitaxel or fulvestrant in PIK3CA/AKT/PTEN-mutated advanced solid tumors.
Cancer
; 129(12): 1919-1929, 2023 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36970876
2.
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer.
Nature
; 515(7528): 558-62, 2014 Nov 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-25428503
3.
First-in-human, phase I study of PF-06647263, an anti-EFNA4 calicheamicin antibody-drug conjugate, in patients with advanced solid tumors.
Int J Cancer
; 145(7): 1798-1808, 2019 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30680712
4.
Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma.
Br J Cancer
; 120(2): 165-171, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30420614
5.
Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers.
Gynecol Oncol
; 154(2): 314-322, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31204078
6.
Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study.
Am J Hematol
; 93(5): 607-614, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29352732
7.
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.
Lancet
; 387(10030): 1837-46, 2016 Apr 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-26970723
8.
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Lancet
; 387(10018): 545-557, 2016 Feb 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-26615328
9.
Detection of an ALK Fusion in Colorectal Carcinoma by Hybrid Capture-Based Assay of Circulating Tumor DNA.
Oncologist
; 22(7): 774-779, 2017 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28507204
10.
Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer.
Oncologist
; 22(4): 375-e30, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28275117
11.
Phase I Study of CHK1 Inhibitor LY2603618 in Combination with Gemcitabine in Patients with Solid Tumors.
Oncology
; 91(5): 251-260, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27598338
12.
Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies.
Oncologist
; 20(5): 499-507, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25882375
13.
An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors.
Invest New Drugs
; 33(1): 148-58, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25260842
14.
Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer.
Oncologist
; 22(10): 1281, 2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29018169
15.
Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT.
Clin Cancer Res
; 28(2): 298-307, 2022 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34716196
16.
Cases in the Management of GEP-NETs: Combination Regimens.
Clin Adv Hematol Oncol
; 14(4 Suppl 6): 11-3, 2016 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-27167993
17.
Association of Tumor Mutational Burden and Immune Gene Expression with Response to PD-1 Blockade by Sasanlimab Across Tumor Types and Routes of Administration.
Target Oncol
; 16(6): 773-787, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34694529
18.
Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study.
Clin Cancer Res
; 27(12): 3360-3369, 2021 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33568344
19.
A Phase 1b Dose Escalation Trial of NC-6300 (Nanoparticle Epirubicin) in Patients with Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft-tissue Sarcoma.
Clin Cancer Res
; 26(16): 4225-4232, 2020 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32381487
20.
Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers.
Clin Cancer Res
; 14(19): 6296-301, 2008 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18829512